activity. Both agents significantly lessened peak edema formation at 24 h and facilitated the recovery of motor function for 0%14 days postinjury. In addition, TBP atten uated disruption of the blood-brain barrier and protected hippocampal cells. PTX significantly lowered the brain TNFa level (by �80%), and TBP completely abolished the activity of recombinant human TNF when they were added at the same time in the in vitro bioassay. We sug gest, therefore. that a decrease in TN Fa level or the in hibition of its activity is accompanied by reduced brain damage. Key Words: Tumor necrosis factor alpha (TNFa)-Brain injury-Pentoxifylline-Tumor necrosis factor binding protein.
to morbidity and mortality in a variety of diseases. Tracy and Cerami, in their review of the biology of TNFa, emphasize its potential as a therapeutic tar get due to its broad scope of injurious and beneficial effects (1994) . A rat model of closed head injury (CHI) has been developed in our laboratory (Sha pira et aI., 1988), and we have described the acti vation of an inflammatory pathway, namely, phos pholipase A2, and increased eicosanoid production (Shohami et aI., 1987 (Shohami et aI., , 1989 . We have demonstrated that following CHI in the rat, there is an increase in TNFa and interleukin-6 (lL-6) production in the cortical tissue adjacent to the site of injury (Sho hami et aI., 1994) .
Since cytokine activity was identified as early as 1 h post-CHI, before infiltration of inflammatory cells is detectable (Shapira et aI., 1988) , the rise in cytokines has been attributed to increased cytokine production by resident brain cells (astrocytes and microglia) rather than to its release from invading monocytes. Assuming that elevated TNFa levels play a detrimental role in the pathophysiology of CHI, the present study was designed to determine the effects of TNFa inhibition on the development of cerebral edema as well as on neurological dys function and hippocampal cell loss after CHI. To this end, two pharmacological agents acting via dif ferent mechanisms were used. Pentoxifylline (PTX), a methylxanthine, has been known for many years for its hemorrheological properties. This drug has been shown to prevent or attenuate the production of TNFa induced by bac terial lipopolysaccharides (LPS) both in vitro (Strie ter et aI., 1988) and in vivo (Zabel et aI., 1989) at the transcriptional level (Doherty et aI., 1991) . TNFa binding protein (TBP) is a cysteine-rich glycopro tein identified and purified from human urine (Pee tre et aI., 1988; Seckinger et aI. , 1988; Engelmann et aI. , 1989) . TBP corresponds to a soluble fragment of the cell-surface TNFa receptor (TNFa-R) gener ated by proteolytic cleavage of the extracellular binding domain (Nophar et aI. , 1990) . It displays a sequence homology to the extracellular portions of the TNF-R p80 chain and to nerve growth factor. TBP is a physiological inhibitor of TNFa, which acts in vitro by competing with the cell-surface TN Fa receptor. We hypothesized that if TNFa plays a part in the pathophysiology of CHI, TBP might counteract its effect and find potential use as a therapeutic agent in our CHI. Indeed, our results support the notion that TN Fa is a harmful mediator in CHI, and its suppression by both agents corre lates with improved recovery following brain injury.
MATERIALS AND METHODS

Closed head injury model
Male Sabra rats (Hebrew University strain) weighing 200-220 g were used. CHI was induced under ether an esthesia by a calibrated weight-drop device that falls over the exposed skull, covering the left hemisphere 1-2 mm lateral to the midline in the mid coronal plane, as de scribed previously (Shapira et a!., 1988) . Rats were kept according to the institutional regulations of the Animal Care Committee.
Neurological evaluation
Rats were evaluated on the basis of clinical criteria, which include reflexes and motor functions, and were graded according to the neurological severity score (NSS) 1 h after CHI (Table 1) . Rats with a score of 15-20 (>90% of the injured animals) were considered severely injured and were included in the study. At various times post CHI (24 h to 2 weeks) the animals were reevaluated. The difference between the new score and that at 1 h was defined as the extent of recovery (�NSS) and was used to assess the neuroprotective properties of the drugs. The greater the difference, the better the recovery. At 24 h post-CHI, the rats were decapitated, and their brains were removed. Since we had shown that the region adjacent to the core of injury develops the highest degree of edema, samples of this region were taken to assess drug effectiveness. The water content in a -20-mg seg ment of cortical tissue adjacent to the site of injury was measured, using the dry/wet weight ratio, as described by Shapira et a!. (1988) .
Evaluation of edema
Evaluation of BBB integrity
Blood-brain barrier (BBB) integrity was tested using the Evans Blue dye extravasation method. Evans Blue was injected i.v. 3 or 23 h after CHI, and 1 h later the animals were perfused with saline, their brains were re moved, the dye was extracted, and its fluorescence was determined (Uyama et a!., 1988).
TNFa determination
TNFa titer was determined by a cytotoxicity assay. Brain extracts were bioassayed as described previously (Sher et aI., 1990 , Shohami et aI., 1994 , using the BALB/c CL. 7 line as target cells. Briefly, cells were plated in Dulbecco's Modified Eagle's Medium contain ing 5% fetal calf serum. After 24 h, threefold dilutions of the brain extracts were added to the target cells, followed by the addition of actinomycin D (Sigma, St. Louis, MO, U.S.A.). The cultures were incubated for 20 h, stained with 2% crystal violet, rinsed, and dried. Destruction of CL. 7 cells was assessed by measuring the absorbance of the stained cells (550 nm) with an MR 700 microplate reader (Dynatech, Farmingdale, NY, U.S.A.).
The TNFex titer (Sso), defined as the reciprocal of the dilution of test extract required to destroy 50% of the target cell monolayer, was determined. Various dilutions of a known concentration of recombinant TNFex were added to the target cells to quantify the Sso, and the data were converted into picograms per milligram of tissue protein. The specificity of TNFex cytotoxicity was con firmed using anti-TNFex antibodies in the same assay, as has been described (Shohami et aI., 1994) . The capacity of TBP to neutralize TNFex activity was demonstrated in vitro by coadministration of recombinant human TNFex (rh-TNFex) and TBP in the bioassay.
Neuropathological analysis
Fourteen days post-CHI rats were reanesthetized with ether, and their brains were perfused transcardially with 4% formaldehyde. The brains were removed for histo pathological evaluation, and 6-fLm-thick coronal sections were cut using a microtome and stained with hematoxylin and eosin. Hippocampal damage was quantified under a light microscope (Nikon) by an uninformed observer by counting the number of viable and dead cells in the CAI_3 fields of the hippocampus.
Agents PTX (Sigma) was used as a stock solution of 4 mg/ml in saline. Traumatized rats were injected i. v. with PTX (20 mg/kg) immediately after induction of CHI. TBP was the generous gift of Interpharm Laboratories Ltd. (Rehovot, Israel). A stock solution of 1 mg/ml saline was used, and a dose of 1 mg/kg was administered i.v. within 5 min of CHI. Recombinant human TNFex was obtained from Genetech Inc. (San Francisco, CA, U.S.A.).
Experimental protocol
Rats were subjected to CHI and treated with the tested agent or its vehicle immediately after induction of trauma. NSS was assessed 1 h later, and the animals were re turned to their cages. NSS was reevaluated at 24, 48, and 72 h and at 7 and 14 days, and �NSS was calculated at each time point. Other groups of rats were decapitated 24 h post-CHI for determination of water content or at 4 or 24 h for evaluation of· BBB integrity. For measuring TNFex levels, groups of rats were traumatized in parallel, treated with the different agents, and decapitated 4 h post-CHI, when TNFex accumulation peaks (Shohami et aI., 1994) .
To further assess the role of endogenous TNFex in the pathophysiology of CHI, a group of rats were injected intracerebrally, into the right lateral ventricle, with 24 fLg of rh-TNFex (in 30 fLl of saline) 5 min before CHI. Within 5 min of CHI the rats were injected i.v. with PTX, and their NSS and water content were evaluated 24 h later.
Statistical analysis
Percentage water content, TNFex levels, and percent age cell loss are presented as the mean ± SD and com-J Cereb Blood Flow Metab, Vol. 16. No.3, 1996 pared using the two-tailed Student's t test. Clinical recov ery, expressed as �NSS, is shown as the median (range) and compared by the two tailed nonparametric Mann Whitney test. The level of significance was p < 0.05.
RESULTS
Effect of PTX
We first determined whether PTX attenuates TNFa production in our model of CHI. Cortical tissue of the contused hemisphere 4 h post-CHI contained 2.16 ± 1.89 ng TNFa/mg protein in the control traumatized rats, whereas the nontrauma tized rats had undetectable levels of the cytokine. The TNFa level was significantly suppressed after PTX treatment: 0.44 ± 0.39 ng/mg protein (p = 0.025, n = 8 rats per group).
Brain tissue water content was determined at 24 h, the time of peak edema formation in our CHI model. As can be seen in Fig. lA rats had a significantly lower water content than did the controls (83.1 ± 1.13 versus 84.7 ± 1.33%, p = 0.0125). We then addressed the functional state of the traumatized rats and compared the ilNSS of control and PTX-treated rats for 14 days postinjury. NSS was assessed at 24, 48, and 72 h as well as 1 and 2 weeks post-CHI. At each of these time points, the ilNSS of the PTX-treated rats was significantly higher than that of the control, untreated CHI rats, indicating better recovery (Fig. IB) . The effect of PTX on BBB integrity was evalu ated at 4 h and 24 h, according to the amount of Evans Blue accumulated in the brain. At 4 h post CHI, in the contused hemisphere of the PTX treated rats, there was 75 ± 17.9 ng dye/mg tissue (n = 7), compared with 117 ± 22.6 (n = 7) in the controls (this difference did not reach significance). At 24 h post-CHI the level of dye was identical in the two groups (229 ± 131 and 233 ± 90 ng dye/mg tissue in the PTX-treated and untreated rats, re spectively).
We next tested whether rh-TNFa injected before CHI would reverse the protective effect of PTX given 5 min after injury. Indeed, the ilNSS of the PTX-treated rats at 24 h was 7 (range 5-9, n = 8), while that of the traumatized rats treated with rh TNFa and PTX was 6 (range 5-7, n = 9), p = 0.02, Mann Whitney test. This value was not signifi cantly different from that obtained for the control (traumatized, untreated) rats, indicating that rh TNFa reversed the beneficial effect of PTX on the clinical outcome. In contrast, the water content of these two groups was similar and significantly lower than that of the control, indicating that rh-TNF a did not abolish the effect of PTX on edema.
The effect exerted by PTX on neurons in the hip pocampal CA2 and CA3 regions was assessed by counting the number of viable cells following treat ment with this agent. In CA2: 23 ± 16.7% dead cells were found in the controls vs 10.8 ± 18.3% in the PTX-treated rats. In CA3: cell death was 32.7 ± 18.9% in the control non-treated rats (n = 5), vs 20.5 ± 14.5% in the PTX-treated rats (n = 8). The differences were not significant.
Effect of TBP
The effect of TBP on edema formation and func tional recovery (ilNSS) after CHI is evident in Fig.  I . Less water accumulated at the site of injury in the TBP-treated rats compared with that in untreated rats after a similar degree of injury (81.16 ± 2.32, n = 11, versus 84.17 ± 1.33%, n = 9; p = 0.007, two-tailed t test; Fig. 1 A) . In addition, recovery of motor functions was significantly facilitated in the TBP-treated rats during the 2-week follow-up ( Fig.   IB ). At all time points, the ilNSS of the TBP treated rats was significantly higher (p < 0.05) than that of the controls, indicating better recovery of motor functions. The effect of TBP on the disrup tion of the BBB was examined at 4 and at 24 h post-CHI. Whereas at 4 h the levels of Evans Blue in the TBP-treated rats were similar to those in the control, at 24 h, they were significantly lower: 76.6 ± 42.8 (n = 6) versus 233.4 ± 117.9 (n = 9, p < 0.01).
Examining cell viability in the hippocampus showed that there was significantly less cell damage in the CA2 and CA3 regions of the TBP-treated rats (n = 7) compared with that in the untreated rats (n = 5). In the CA2 it was 3.42 ± 1.44 versus 23.02 ± 16.7% (p < 0.05), and in the CA3 it was 14.5 ± 10.4% versus 32.7 ± 18.9% (p = 0.056, marginally si & nificant). The protective effect of TBP on hippo campal cells is shown in Fig. 2 .
In an attemp t to verify that TBP treatment indeed reduced brain TNFa activity, brain extracts were prepared from the traumatized, TBP-treated rats and tested in the bioassay. The results show that there was no reduction in TNFa activity in the brain homogenates of the treated rats (SSG of 61 ± 35, n = 12, in the control, untreated rats, versus 151 ± 106, n = 7, in the TBP-treated rats, which was not sig nificant). However, the activity was totally abol ished when TBP was added in vitro along with rh TNFa (S SG of 1,919 for the rh-TNFa, and 0 for the rh-TNFa added together with TBP).
DISCUSSION
The results of the present study support the no tion that TNFa mediates at least some of the harm ful events occurring following traumatic brain in jury. Indeed, PTX reduced the early and transient surge of TN Fa activity in the brain following CHI. This finding concurs with earlier reports by a num ber of investigators regarding the drug's mechanism of action (Strieter et aI., 1988; Doherty et aI., 1991) . We showed that PTX also ameliorated motor dys function, even as late as 14 days postinjury, and reduced brain edema at 24 h, the time of maximal edema (Shapira et aI., 1988) . We, therefore, suggest that the low level of TNFa is associated with the cerebroprotection observed under these conditions. We previously showed that there is a transient in crease in TN Fa production after CHI, starting at 1 h, peaking at 4 h, and terminating at � 12 h postin jury (Shohami et al. 1994 ).
In the present study, PTX was administered only once, immediately after CHI, whereas the protec tive effect was evident even as late as 2 weeks postinjury. It is conceivable that the drug, by inter- fering with the production of a harmful mediator, prevents progressive damage. TNFa may affect a cascade of other mediators (e.g., IL-6) during the very early post-CHI stages (�6 h). Reversal of the PTX effect on clinical recovery, achieved by co administration of rh-TNFa, strongly supports the role of TN Fa in mediating motor impairment occur ring after injury. Although TNFa reportedly dam ages cerebral endothelial cells (Terada et aI., 1992) and increases BBB permeability (Megyeri et aI. , 1992) , i.c.v. administration of rh-TNFa did not abolish the effect of PTX on brain edema in our model. This finding implies that edema formation may be mediated by various mechanisms in which other mediators (cytokines, free radicals, ei cosanoids, etc.) are involved. This notion is sup ported by our present finding that PTX is not a po tent inhibitor of BBB impairment, i.e., its effect on water content may be related to cytotoxic rather than to vasogenic edema.
One may also speculate that the effect of PTX is not specific to TN Fa suppression and that it can affect other cytokines. Parhar et al. (1993) have found that LPS-induced cytokine (IL-1a, IL-2, IL-6, TNFa, and gamma interferon) as well as surface J Cereb Blood Flow Metab, Vol. 16, No.3, 1996 receptor expression (IL-1a, IL-2, and TNFa) were affected by PTX. Our results agree with those of Quagliarello et aL (1991) , who studied the influence of IL-1 and TNFa on BBB permeability. They showed that the two cytokines acted synergistically to disrupt BBB function, whereas TNFa alone was less effective as an independent inducer of BBB injury. One could, therefore, speculate that in our model of CHI, the production of various cytokines is triggered, leading to a deleterious additive effect in the traumatized rat.
A more direct pharmacological approach to over coming the negative effects of various cytokines is neutralization of these properties by specific anti bodies or by soluble receptors. This strategy has been successfully applied by Rothwell and col leagues, who showed that the antagonist of the IL-1 receptor inhibited neuronal death in a model of fo cal cerebral ischemia (ReIton and Rothwell, 1992) and fluid percussion (Toulmond and Rothwell, 1995) . In animal models of endotoxic and septic shock, several investigators have shown that devel opment of shock and tissue injury could be pre vented by anti-TNF antibodies (Tracy et aI., 1987; Hinshaw et aI. , 1989; Emerson et aI., 1992) ,
In the present study we treated the traumatized rats with TBP within 1 h of CHI and found reduced edema and BBB impairment at 24 h, a significant amelioration of neurological dysfunction � 14 days post-CHI, and protection of hippocampal neurons. TBP, a specific anti-TN Fa compound, acts as a sol uble fragment of the cell-surface TN Fa receptor and binds this cytokine, thus neutralizing its activ ity. TBP, a natural molecule that interferes with TNFa activity, prevents the interaction of the latter with the target cell. The apparent ineffectiveness of TBP in the bioassay of brain extracts of TBP treated rats may be attributed to the fact that the brain homogenates were prepared by sonicating the brain tissue. This procedure may have dissociated the complex and liberated the free TN Fa that had accumulated in the brain after injury, yielding the high activity observed in the bioassay.
In contrast to the PTX-treated brains, where TNFa production was inhibited, in the TBP-treated rats, TNFa was produced in response to injury, and was probably neutralized thereafter, resulting in the improved in vivo outcome. However, the complex TNF-TBP may be unstable under the extraction conditions, leading to the release of free TNFa and the expression of its activity in the in vitro assay system. Indeed, upon co-administration of rh TNFa and TBP to the target cells, there was a loss of activity. We therefore assume that TBP acts to neutralize the direct or indirect actions of TNFa in the brain.
In their study of the pharmacokinetics and tissue distribution of TBP in mice, Gascon et al. (1992) found that only a minor fraction of the i. v .-injected TBP was present in the brain, probably owing to its inability to cross the BBB. In our model of CHI, there is early impairment of the BBB, which may facilitate the penetration of nonpermeable mole cules and could account for the observed effect of TBP on brain function. Our results, showing the ameliorative effects of PTX and TBP on CHI out come, could be interpreted as showing the involve ment of TNFa, and probably of other cytokines ac tivated by TNFa, in the pathophysiology of brain irijury. If so, neutralization of its deleterious effects could be a novel approach to the treatment of CHI patients.
